Study for the influencing factors of adverse drug reaction of metformin and its correlation with gene polymorphism

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023116

Enrollment

Unknown

Registered

2019-05-11

Start date

2019-05-11

Completion date

Unknown

Last updated

2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic diseases

Interventions

The experimental group:Metformin

The control group:The placebo

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. patients newly diagnosed with type 2 diabetes; 2. Patients with type 2 diabetes whose blood glucose and other drug regimens have been stable for 8 weeks or more; 3. Patients with hyperinsulinemia/polycystic ovary syndrome who are proposed to be treated with metformin.

Exclusion criteria

Exclusion criteria: 1. diabetes mellitus with pregnancy; 2. diabetic ketosis, ketoacidosis, lactic acidosis, hyperosmolar hyperglycemia coma, acute pancreatitis and other acute complications; 3. severe hepatorenal insufficiency; 4. allergic to biguanides; 5. have severe gastrointestinal diseases or take medicine or food causing gastrointestinal disorders for nearly 2 weeks; 6. patients with tumor and immune system diseases.

Design outcomes

Primary

Measure	Time frame
Gene polymorphism;Gastrointestinal reaction;BMI;Hemoglobin a1c;Blood sugar;Blood fat;	—

Secondary

Measure	Time frame
Biochemical examination;	—

Countries

China

Contacts

Public ContactDongfang Liu

The Second Hospital Affiliated to Chongqing Medical University

ldf023023@qq.com+86 18623407751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026